Polymorphism rs2275913 of Interleukin-17A is related to more intensive therapy with disease-modifying anti rheumatic drugs in Mexican patients with Rheumatoid Arthritis

Maximiliano García de la Peña, René Méndez Cruz, Efraín Garrido Guerrero, Aida Galicia López, Glustein Pozo Molina, Norma Estela Herrera González

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

AIM: The study has two aims: 1) to evaluate the association of IL-17 polymorphism rs2275913 with RA severity and 2) to evaluate if this particular SNP is associated with susceptibility for RA in Mexican patients.METHODS: Seventy-six RA patients and ninety-four healthy controls were included in the study. RA patients were evaluated according to DAS 28. Treatment with DMARD'S was prescribed and radiological damage was evaluated according to the Larsen method. A case-control study was used. Oral epithelial cells were obtained as source for genetic material. DNA was amplified using PCR. Subsequently, a RFLP was carried out. Finally, in order to confirm the IL-17 SNP rs2275913 presence, direct sequencing of the DNA was performed.RESULTS: A significant difference was observed between the RA patients and controls when the prevalence of IL-17 SNP rs2275913 was compared. There was a statistically significant disparity among the two groups with an OR of 5.6 (95%CI 1.5 - 20.9, P=<0.01). In this study was observed that the RA patients who were positive for the IL-17 polymorphism rs2275913 required 3 DMARDs to control the disease compared to 32% of the patients who were negative for the IL-17 polymorphism rs2275913, OR 6.6 (95%CI 1.6 - 27.0, P<0.01).CONCLUSION: This study draws two main conclusions: 1) The presence of IL-17 polymorphism rs2275913 is closely related to a more severe form of the disease and as a result, a higher number of DMARDs required to control it, 2) The presence of IL-17 polymorphism rs2275913 may confer a risk of developing RA in Mexican carriers.
Original languageAmerican English
Pages (from-to)155-161
Number of pages138
JournalActa reumatologica portuguesa
StatePublished - 1 Apr 2017

Fingerprint

Antirheumatic Agents
Interleukin-17
Rheumatoid Arthritis
Single Nucleotide Polymorphism
amsonic acid
Therapeutics
DNA Sequence Analysis
Restriction Fragment Length Polymorphisms
Case-Control Studies
Epithelial Cells
Polymerase Chain Reaction
DNA
Genes

Cite this

García de la Peña, Maximiliano ; Méndez Cruz, René ; Garrido Guerrero, Efraín ; Galicia López, Aida ; Pozo Molina, Glustein ; Herrera González, Norma Estela. / Polymorphism rs2275913 of Interleukin-17A is related to more intensive therapy with disease-modifying anti rheumatic drugs in Mexican patients with Rheumatoid Arthritis. In: Acta reumatologica portuguesa. 2017 ; pp. 155-161.
@article{33bdf9d6af1643f9926a71b37589468d,
title = "Polymorphism rs2275913 of Interleukin-17A is related to more intensive therapy with disease-modifying anti rheumatic drugs in Mexican patients with Rheumatoid Arthritis",
abstract = "AIM: The study has two aims: 1) to evaluate the association of IL-17 polymorphism rs2275913 with RA severity and 2) to evaluate if this particular SNP is associated with susceptibility for RA in Mexican patients.METHODS: Seventy-six RA patients and ninety-four healthy controls were included in the study. RA patients were evaluated according to DAS 28. Treatment with DMARD'S was prescribed and radiological damage was evaluated according to the Larsen method. A case-control study was used. Oral epithelial cells were obtained as source for genetic material. DNA was amplified using PCR. Subsequently, a RFLP was carried out. Finally, in order to confirm the IL-17 SNP rs2275913 presence, direct sequencing of the DNA was performed.RESULTS: A significant difference was observed between the RA patients and controls when the prevalence of IL-17 SNP rs2275913 was compared. There was a statistically significant disparity among the two groups with an OR of 5.6 (95{\%}CI 1.5 - 20.9, P=<0.01). In this study was observed that the RA patients who were positive for the IL-17 polymorphism rs2275913 required 3 DMARDs to control the disease compared to 32{\%} of the patients who were negative for the IL-17 polymorphism rs2275913, OR 6.6 (95{\%}CI 1.6 - 27.0, P<0.01).CONCLUSION: This study draws two main conclusions: 1) The presence of IL-17 polymorphism rs2275913 is closely related to a more severe form of the disease and as a result, a higher number of DMARDs required to control it, 2) The presence of IL-17 polymorphism rs2275913 may confer a risk of developing RA in Mexican carriers.",
author = "{Garc{\'i}a de la Pe{\~n}a}, Maximiliano and {M{\'e}ndez Cruz}, Ren{\'e} and {Garrido Guerrero}, Efra{\'i}n and {Galicia L{\'o}pez}, Aida and {Pozo Molina}, Glustein and {Herrera Gonz{\'a}lez}, {Norma Estela}",
year = "2017",
month = "4",
day = "1",
language = "American English",
pages = "155--161",
journal = "Acta reumatologica portuguesa",
issn = "0303-464X",
publisher = "Sociedade Portuguesa de Reumatologia",

}

Polymorphism rs2275913 of Interleukin-17A is related to more intensive therapy with disease-modifying anti rheumatic drugs in Mexican patients with Rheumatoid Arthritis. / García de la Peña, Maximiliano; Méndez Cruz, René; Garrido Guerrero, Efraín; Galicia López, Aida; Pozo Molina, Glustein; Herrera González, Norma Estela.

In: Acta reumatologica portuguesa, 01.04.2017, p. 155-161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polymorphism rs2275913 of Interleukin-17A is related to more intensive therapy with disease-modifying anti rheumatic drugs in Mexican patients with Rheumatoid Arthritis

AU - García de la Peña, Maximiliano

AU - Méndez Cruz, René

AU - Garrido Guerrero, Efraín

AU - Galicia López, Aida

AU - Pozo Molina, Glustein

AU - Herrera González, Norma Estela

PY - 2017/4/1

Y1 - 2017/4/1

N2 - AIM: The study has two aims: 1) to evaluate the association of IL-17 polymorphism rs2275913 with RA severity and 2) to evaluate if this particular SNP is associated with susceptibility for RA in Mexican patients.METHODS: Seventy-six RA patients and ninety-four healthy controls were included in the study. RA patients were evaluated according to DAS 28. Treatment with DMARD'S was prescribed and radiological damage was evaluated according to the Larsen method. A case-control study was used. Oral epithelial cells were obtained as source for genetic material. DNA was amplified using PCR. Subsequently, a RFLP was carried out. Finally, in order to confirm the IL-17 SNP rs2275913 presence, direct sequencing of the DNA was performed.RESULTS: A significant difference was observed between the RA patients and controls when the prevalence of IL-17 SNP rs2275913 was compared. There was a statistically significant disparity among the two groups with an OR of 5.6 (95%CI 1.5 - 20.9, P=<0.01). In this study was observed that the RA patients who were positive for the IL-17 polymorphism rs2275913 required 3 DMARDs to control the disease compared to 32% of the patients who were negative for the IL-17 polymorphism rs2275913, OR 6.6 (95%CI 1.6 - 27.0, P<0.01).CONCLUSION: This study draws two main conclusions: 1) The presence of IL-17 polymorphism rs2275913 is closely related to a more severe form of the disease and as a result, a higher number of DMARDs required to control it, 2) The presence of IL-17 polymorphism rs2275913 may confer a risk of developing RA in Mexican carriers.

AB - AIM: The study has two aims: 1) to evaluate the association of IL-17 polymorphism rs2275913 with RA severity and 2) to evaluate if this particular SNP is associated with susceptibility for RA in Mexican patients.METHODS: Seventy-six RA patients and ninety-four healthy controls were included in the study. RA patients were evaluated according to DAS 28. Treatment with DMARD'S was prescribed and radiological damage was evaluated according to the Larsen method. A case-control study was used. Oral epithelial cells were obtained as source for genetic material. DNA was amplified using PCR. Subsequently, a RFLP was carried out. Finally, in order to confirm the IL-17 SNP rs2275913 presence, direct sequencing of the DNA was performed.RESULTS: A significant difference was observed between the RA patients and controls when the prevalence of IL-17 SNP rs2275913 was compared. There was a statistically significant disparity among the two groups with an OR of 5.6 (95%CI 1.5 - 20.9, P=<0.01). In this study was observed that the RA patients who were positive for the IL-17 polymorphism rs2275913 required 3 DMARDs to control the disease compared to 32% of the patients who were negative for the IL-17 polymorphism rs2275913, OR 6.6 (95%CI 1.6 - 27.0, P<0.01).CONCLUSION: This study draws two main conclusions: 1) The presence of IL-17 polymorphism rs2275913 is closely related to a more severe form of the disease and as a result, a higher number of DMARDs required to control it, 2) The presence of IL-17 polymorphism rs2275913 may confer a risk of developing RA in Mexican carriers.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049440691&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85049440691&origin=inward

M3 - Article

SP - 155

EP - 161

JO - Acta reumatologica portuguesa

JF - Acta reumatologica portuguesa

SN - 0303-464X

ER -